Fanconi anemia (FA) is a rare hereditary disorder characterized by skeletal abnormalities, bone marrow failure, and an increased incidence of cancer. The basic cellular abnormality in FA has been postulated to lie in the DNA repair mechanisms because cells from FA patients display chromosomal breakage, which is particularly remarkable following induction of DNA crosslinks. However, experimental evidence for this hypothesis has been lacking. To test whether DNA repair is really defective in FA cells, we disrupted several FA genes in chicken B cell line DT40. By measuring efficiency of gene conversion and hypermutation at the Immunoglobulin locus, we have shown that DT40 FA mutant cell lines exhibited defects in homologous DNA recombination, and possibly, translesion synthesis. However, levels of sister chromatid exchange, another important cellular event mediated by HR, were not reduced, possibly indicating the role of FA genes only in a subpathway of HR. Our results indicate that chicken DT40 cells could be highly useful in molecular dissection of basic biochemical processes, which are deficient in a human genetic disorder.

1.
Arakawa H, Buerstedde JM: Immunoglobulin gene conversion: Insights from bursal B cells and the DT40 cell line. Dev Dyn 229:458–464 (2004).
2.
Arakawa H, Saribasak H, Buerstedde JM: Activation-induced cytidine deaminase initiates immunoglobulin gene conversion and hypermutation by a common intermediate. PLoS Biol 2:E179 (2004).
3.
Bezzubova O, Silbergleit A, Yamaguchi-Iwai Y, Takeda S, Buerstedde JM: Reduced X-ray resistance and homologous recombination frequencies in a RAD54-/- mutant of the chicken DT40 cell line. Cell 89:185–193 (1997).
4.
Bridge WL, Vandenberg CJ, Franklin RJ, Hiom K: The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair. Nat Genet 37:953–957 (2005).
5.
Buerstedde JM, Takeda S: Increased ratio of targeted to random integration after transfection of chicken B cell lines. Cell 67:179–188 (1991).
6.
Buerstedde JM, Reynaud CA, Humphries EH, Olson W, Ewert DL, Weill JC: Light chain gene conversion continues at high rate in an ALV-induced cell line. EMBO J 9:921–927 (1990).
7.
Cox MM: Recombinational DNA repair of damaged replication forks in Escherichia coli: questions. Annu Rev Genet 35:53–82 (2001).
8.
Cox MM, Goodman MF, Kreuzer KN, Sherratt DJ, Sandler SJ, Marians KJ: The importance of repairing stalled replication forks. Nature 404:37–41 (2000).
9.
D’Andrea AD, Grompe M: The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 3:23–34 (2003).
10.
Fujimori A, Tachiiri S, Sonoda E, Thompson LH, Dhar PK, et al: Rad52 partially substitutes for the Rad51 paralog XRCC3 in maintaining chromosomal integrity in vertebrate cells. EMBO J 20:5513–5520 (2001).
11.
Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, et al: Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 7:249–262 (2001).
12.
Hickson ID: RecQ helicases: caretakers of the genome. Nat Rev Cancer 3:169–178 (2003).
13.
Hinz JM, Nham PB, Salazar EP, Thompson LH: The Fanconi anemia pathway limits the severity of mutagenesis. DNA Repair (Amst) 5:875–884 (2006).
14.
Hirano S, Yamamoto K, Ishiai M, Yamazoe M, Seki M, et al: Functional relationships of FANCC to homologous recombination translesion synthesis and BLM. EMBO J 24:418–427 (2005).
15.
Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, et al: Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297:606–609 (2002).
16.
Hussain S, Witt E, Huber PA, Medhurst AL, Ashworth A, Mathew CG: Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1. Hum Mol Genet 12:2503–2510 (2003).
17.
Johnson RD, Liu N, Jasin M: Mammalian XRCC2 promotes the repair of DNA double-strand breaks by homologous recombination. Nature 401:397–399 (1999).
18.
Kannouche PL, Wing J, Lehmann AR: Interaction of human DNA polymerase eta with monoubiquitinated PCNA: a possible mechanism for the polymerase switch in response to DNA damage. Mol Cell 14:491–500 (2004).
19.
Kitao H, Yamamoto K, Matsushita N, Ohzeki, M Ishiai M, Takata M: Functional interplay between BRCA2/FANCD1 and FANCC in DNA repair. J Biol Chem 281:21312–21320 (2006).
20.
Komori K, Fujikane R, Shinagawa H, Ishino Y: Novel endonuclease in Archaea cleaving DNA with various branched structure. Genes Genet Syst 77:227–241 (2002).
21.
Levitus M, Rooimans MA, Steltenpool J, Cool NF, Oostra AB, et al: Heterogeneity in Fanconi anemia: evidence for two new genetic subtypes. Blood 103:2498–2503 (2004).
22.
Levitus M, Waisfisz Q, Godthelp BC, Vries Y, Hussain S, et al: The DNA helicase BRIP1 is defective in Fanconi anemia complementation group. J Nat Genet 37:934–935 (2005).
23.
Levran O, Attwooll C, Henry RT, Milton KL, Neveling K, et al: The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet 37:931–933 (2005).
24.
Litman R, Peng M, Jin Z, Zhang F, Zhang J, et al: BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 8:255–265 (2005).
25.
Meetei AR, de Winter JP, Medhurst AL, Wallisch M, Waisfisz Q, et al: A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet 35:165–170 (2003a).
26.
Meetei AR, Sechi S, Wallisch M, Yang D, Young MK, et al: A multiprotein nuclear complex connects Fanconi anemia and Bloom syndrome. Mol Cell Biol 23:3417–3426 (2003b).
27.
Meetei AR, Levitus M, Xue Y, Medhurst AL, Zwaan M, et al: X-linked inheritance of Fanconi anemia complementation group B. Nat Genet 36:1219–1224 (2004).
28.
Meetei AR, Medhurst AL, Ling C, Xue Y, Singh TR, et al: A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M. Nat Genet37:958–963 (2005).
29.
Mosedale G, Niedzwiedz W, Alpi A, Perrina F, Pereira-Leal JB, Jet al: The vertebrate Hef ortholog is a component of the Fanconi anemia tumor-suppressor pathway. Nat Struct Mol Biol 12:763–771 (2005).
30.
Nakanishi K, Taniguchi T, Ranganathan V, New HV, Moreau LA, et al: Interaction of FANCD2 and NBS1 in the DNA damage response. Nat Cell Biol 4:913–920 (2002).
31.
Niedzwiedz W, Mosedale G, Johnson M, Ong CY, Pace P, Patel KJ: The Fanconi anaemia gene FANCC promotes homologous recombination and error-prone DNA repair. Mol Cell 15:607–620 (2004).
32.
Paques F, Haber JE: Multiple pathways of recombination induced by double-strand breaks in Saccharomyces cerevisiae. Microbiol Mol Biol Rev 63:349–404 (1999).
33.
Park WH, Margossian S, Horwitz AA, Simons AM, D’Andrea AD, Parvin JD: Direct DNA binding activity of the Fanconi anemia D2 protein. J Biol Chem 280:23593–23598 (2005).
34.
Prakash S, Johnson RE, Prakash L: Eukaryotic translesion synthesis DNA polymerases: specificity of structure and function. Annu Rev Biochem 74:317–353 (2005).
35.
Sasaki MS: Is Fanconi’s anaemia defective in a process essential to the repair of DNA cross links? Nature 257:501–503 (1975).
36.
Sasaki MS, Tonomura A: A high susceptibility of Fanconi’s anemia to chromosome breakage by DNA cross-linking agents. Cancer Res 33:1829–1836 (1973)
37.
Simpson LJ, Sale JE: Rev1 is essential for DNA damage tolerance and non-templated immunoglobulin gene mutation in a vertebrate cell line. EMBO J 22:1654–1664 (2003).
38.
Sonoda E, Sasaki MS, Buerstedde JM, Bezzubova O, Shinohara A, et al: Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. EMBO J 17:598–608 (1998).
39.
Sonoda E, Sasaki MS, Morrison C, Yamaguchi-Iwai Y, Takata M, Takeda S: Sister chromatid exchanges are mediated by homologous recombination in vertebrate cells. Mol Cell Biol 19:5166–5169 (1999).
40.
Sonoda E, Takata M, Yamashita YM, Morrison C, Takeda S: Homologous DNA recombination in vertebrate cells. Proc Natl Acad Sci USA 98:8388–8394 (2001).
41.
Stewart GS, Wang B, Bignell CR, Taylor AM, Elledge SJ: MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature 421:961–966 (2003).
42.
Takata M, Sasaki MS, Sonoda E, Fukushima T, Morrison C, et al: The Rad51 paralog Rad51B promotes homologous recombinational repair. Mol Cell Biol 20:6476–6482 (2000).
43.
Takata M, Sasaki MS, Tachiiri S, Fukushima T, Sonoda E, et al: Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogs. Mol Cell Biol 21:2858–2866 (2001).
44.
Taniguchi T, D’Andrea AD: Molecular pathogenesis of Fanconi anemia: recent progress. Blood 107:4223–4233 (2006).
45.
Taniguchi T, Garcia-Higuera I, Andreassen PR, Gregory RC, Grompe M, D’Andrea AD: S-phase-specific interaction of the Fanconi anemia protein FANCD2 with BRCA1 and RAD51. Blood 100:2414–2420 (2002).
46.
Thompson LH, Hinz JM, Yamada NA, Jones NJ: How Fanconi anemia proteins promote the four Rs: Replication recombination repair and recovery. Environ Mol Mutagen 45:128–142 (2005).
47.
Venkitaraman AR: Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108:171–182 (2002).
48.
Wang X, Andreassen PR, D’Andrea AD: Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Mol Cell Biol 24:5850–5862 (2004).
49.
Watanabe K, Tateishi S, Kawasuji M, Tsurimoto T, Inoue H, Yamaizumi M: Rad18 guides polWη to replication stalling sites through physical interaction and PCNA monoubiquitination. EMBO J 23:3886–3896 (2004).
50.
West SC: Molecular views of recombination proteins and their control. Nat Rev Mol Cell Biol 4:435–445 (2003).
51.
Yamamoto K, Hirano S, Ishiai M, Morishima K, Kitao H, et al: Fanconi anemia protein FANCD2 promotes immunoglobulin gene conversion and DNA repair through a mechanism related to homologous recombination. Mol Cell Biol 25:34–43 (2005).
52.
Yamamoto K, Ishiai M, Matsushita N, Arakawa H, Lamerdin JE, et al: Fanconi anemia FANCG protein in mitigating radiation- and enzyme-induced DNA double-strand breaks by homologous recombination in vertebrate cells. Mol Cell Biol23:5421–5430 (2003).
53.
Yu X, Chini CC, He M, Mer G, Chen J: The BRCT domain is a phospho-protein binding domain. Science 302:639–642 (2003).
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.